This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The global oncology precision medicine market was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031.
Market Report Coverage - Oncology Precision Medicine
Market Segmentation
- Ecosystem - Precision Therapeutics, Applied Sciences, Digital Health and Information Technology, Precision Diagnostics
- Application - Solid Tumor and Hematological Malignancies
Regional Segmentation
- North America: U.S., Canada
- Europe: Germany, France, Italy, U.K., Spain, and Rest-of- Europe
- Asia-Pacific: Japan, China, India, Australia, South Korea, and Rest-of-Asia-Pacific
- Latin America: Brazil, Mexico, and Rest-of-Latin America
- Rest-of-the-World
Market Growth Drivers
- Increasing Incidence of Cancer Globally
- Decreasing Trial and Error-Based Drug Prescription Through Pharmacogenomics
- Increasing Usage of Predictive Biomarker for Cancer Diagnostics
- Rapid Technological Advancements related to Oncology Precision Medicine
- Decreasing Cost and Increase in the Output of Genomic Sequencing
Market Challenges
- Large Scale Data Integration, Analysis, and Establishment of Secure Data Libraries
- Inadequate Reimbursement Scenario for Precision Medicine
- Lack of Expertise, Education, and Awareness for Precision Medicine Implementation
Market Opportunities
- Unprecedented Improvements in Disease Modelling via In-Silico, In-Vitro, and In-Vivo Methods
- Expansion into the Emerging Markets
- Rising Number of Initiatives for Precision Oncology Research
Key Companies Profiled
Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Pacific Biosciences of California, Inc., PerkinElmer Inc., QIAGEN, Thermo Fisher Scientific Inc., BGI Group, ASURAGEN, INC., Almac Group Ltd., MDxHealth, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Myriad Genetics, Inc., OPKO Health, Inc., Quest Diagnostics Incorporated, Novartis AG
Key Questions Answered in the Report
- How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
- What are the major market drivers, restraints, and opportunities in the global oncology precision medicine market?
- What are the underlying structures resulting in the emerging trends within the global oncology precision medicine market?
- How is each segment of the global oncology precision medicine market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
- What are the key developmental strategies implemented by the major players to sustain in the competitive market?
- What are the key regulatory implications in developed and developing regions for oncology precision medicine?
- Who are the leading players with significant offerings to the global oncology precision medicine market? What is the current market dominance for each of these leading players?
- What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which ecosystem in the oncology precision medicine type has the most promising growth?
- What are the major applications employed in the global oncology precision medicine market? Which is the dominating application?
- Who are the key manufacturers in the global oncology precision medicine market, and what are their contributions? Also, what is the growth potential of each major oncology precision medicine manufacturer?
- What is the scope of the global oncology precision medicine market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which oncology precision medicine technology and end user dominate these regions?
- What are the emerging trends in the global oncology precision medicine market? How are these trends revolutionizing the diagnostic procedure?
- Which technologies are anticipated to break through the oncology precision medicine regime?
- Which companies are anticipated to be highly disruptive in the future and why?
- What are the regulatory procedures that are required to unify the approval process for the emerging oncology precision medicine market? How will these enhance the reimbursement scenario?
- What are the gaps in regularizing oncology precision medicine adoption in regular healthcare routines? How are these gaps being tackled?
Market Overview
Precision medicine is a concept that collectively integrates the outcomes and the endeavors of research and healthcare. The ability to tailor the diagnostics and therapeutics offered to the patients is the key to precision medicine. The combination of biotechnology development, digitization of healthcare, the public investment led to the evolution of the personalization of disease-based therapies. The precision medicine concept is a systematic process aiming to achieve victory over a disease such as cancer. Cancer is the major focus of various precision medicine initiatives, and precision oncology centers around matching the most accurate and precise treatment to each cancer patient on the basis of an individual’s matching genetic profile that could ultimately let them benefit from the treatment offered.
The global oncology precision medicine market was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031.
Factors fueling the growth of the market include increasing incidence of cancer globally, decreasing trial and error-based drug prescription through pharmacogenomics, increasing usage of predictive biomarkers for cancer diagnostics, and rapid technological advancements related to oncology precision medicine.
Within the research report, the market has been segmented based on ecosystem, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the prevalence of cancer globally has created a buzz among companies to invest in oncology precision medicine.
Based on region, North America holds the largest share, owing to rising cancer prevalence and improvised regulatory policies pertaining to precision oncology in the region. However, the Asia-Pacific and Europe regions are anticipated to grow at the fastest CAGR during the forecast period.
Table of Contents
1 Markets
1.1 Industry Outlook
1.1.1 Introduction
1.2 Evolution of Precision Medicine for Cancer Management and Treatment
1.3 Applications of Precision Medicine in Oncology
1.3.1 Identifying Genetic Mutations and Risks of Cancer Through Precision Diagnostics
1.3.2 Promising Technological Developments Supporting Precision Oncology
1.3.2.1 Low-Throughput Genomic Sequencing to High-Throughput Genomic Sequencing
1.3.2.2 Multicell Hybrid Detection to Single-Cell Precision Detection
1.3.2.3 Advancing Applications of ctDNA Detection Technology
1.3.2.4 CRISPR/Cas Technology
1.4 Impact of COVID-19 Pandemic on Global Oncology Precision Medicine Market
1.4.1 Disruption of Oncology Precision Medicine Due to COVID-19
1.4.2 COVID-19 Affecting Supply Chain of Oncology Precision Medicine-Based Therapies
1.4.3 Interruption in Research and Clinical Development and Commercial Operation
1.4.3.1 Research and Clinical Development
1.4.4 Commercial Operation and Access
1.4.5 Navigating Crisis Recovery and Looking to the Future
1.5 Market Dynamics
1.5.1 Impact Analysis
1.5.2 Market Drivers
1.5.2.1 Increasing Incidence of Cancer Globally
1.5.2.2 Decreasing Trial and Error-Based Drug Prescription Through Pharmacogenomics
1.5.2.3 Increasing Usage of Predictive Biomarker for Cancer Diagnostics
1.5.2.4 Rapid Technological Advancements related to Oncology Precision Medicine
1.5.2.5 Decreasing Cost and Increase in the Output of Genomic Sequencing
1.5.3 Restraints
1.5.3.1 Large Scale Data Integration, Analysis, and Establishment of Secure Data Libraries
1.5.3.2 Inadequate Reimbursement Scenario for Precision Medicine
1.5.3.3 Barriers in the Advancement of Precision Medicine
1.5.3.3.1 Regulatory Barriers
1.5.3.4 Lack of Expertise, Education, and Awareness for Precision Medicine Implementation
1.6 Market Opportunities
1.6.1 Unprecedented Improvements in Disease Modelling via In-Silico, In-Vitro, and In-Vivo Methods
1.6.2 Expansion into the Emerging Markets
1.6.3 Rising Number of Initiatives for Precision Oncology Research
1.7 Competitive Landscape
1.7.1 Acquisitions
1.7.2 Synergistic Activities
1.7.3 Product Launches, Approvals, and Upgradations
1.7.4 Business Expansion
1.7.5 Market Share Analysis
1.7.6 Growth Share Analysis
1.7.6.1 Growth Share Analysis (by Application)
1.7.6.2 Growth Share Analysis (by Ecosystem)
1.8 Industry Insights
1.8.1 Legal and Regulatory Framework and Requirements
1.8.2 North America
1.8.2.1 Regulatory Requirements in U.S.
1.8.3 Europe
1.8.3.1 U.K.
1.8.3.1.1 Regulatory Requirements in U.K.
1.8.3.1.1.1 The Cancer Plan
1.8.4 Asia-Pacific
1.9 Legal Requirements and Framework by MHLW
1.1 Legal Requirement and Framework by NMPA
1.11 Patent Analysis
1.11.1 Patent Filing Trend
1.11.1.1 Patent Analysis (by Region)
1.11.1.2 Patent Analysis (by Country)
2 Global Oncology Precision Medicine Market, by Ecosystem, $ Million, 2020-2031
2.1 Overview
2.1.1 Precision Therapeutics
2.1.1.1 Clinical Trials
2.1.1.2 Biomarker Testing
2.1.1.3 Drug Discovery and Research
2.1.1.4 Gene Therapy
2.1.1.5 Cell Therapy
2.1.2 Applied Sciences
2.1.2.1 Genomics
2.1.2.1.1 Polymerase Chain Reaction (PCR)
2.1.2.1.2 Precision Medicine Next-Generation Sequencing
2.1.2.1.3 Genome Editing
2.1.2.1.4 Other Technologies
2.1.2.2 Pharmacogenomics
2.1.2.3 Other Applied Sciences
2.1.3 Digital Health and Information Technology
2.1.3.1 Clinical Decision Support System (CDSS)
2.1.3.2 Big Data Analytics
2.1.3.3 IT Infrastructure
2.1.3.4 Genomics Informatics
2.1.3.5 In-Silico Informatics
2.1.3.6 Mobile Health
2.1.4 Precision Diagnostics
2.1.4.1 Molecular Diagnostics (MDx)
2.1.4.2 Medical Imaging
3 Global Oncology Precision Medicine Market, by Application, $ Million, 2020-2031
3.1 Overview
3.1.1 Solid Tumor
3.1.1.1 Breast Cancer
3.1.1.2 Lung Cancer
3.1.1.3 Colorectal Cancer
3.1.1.4 Prostate Cancer
3.1.1.5 Cervical Cancer
3.1.1.6 Other Cancer
3.1.2 Hematological Malignancies (HMs)
3.1.2.1 Leukemia
3.1.2.2 Lymphoma
3.1.2.3 Myeloma or Multiple Myeloma (MM)
3.1.2.4 Other Hematological Malignancies
4 Global Oncology Precision Medicine Market, by Regions, $ Million, 2020-2031
4.1 Overview
4.2 North America
4.2.1 Key Competitors (by Ecosystem)
4.2.2 North America Oncology Precision Medicine Market (by Application)
4.2.3 Key Trends in the North America Oncology Precision Medicine Market
4.2.4 U.S.
4.2.5 Canada
4.3 Europe
4.3.1 Key Competitors (by Ecosystem)
4.3.2 Europe Oncology Precision Medicine Market (by Application)
4.3.3 Key Trends of Europe Oncology Precision Medicine Market
4.3.4 Germany
4.3.5 U.K.
4.3.6 France
4.3.7 Italy
4.3.8 Spain
4.3.9 Rest-of-Europe
4.4 Asia-Pacific
4.4.1 Key Competitors (by Ecosystem)
4.4.2 Asia-Pacific Oncology Precision Medicine Market (by Application)
4.4.3 Key Trends in the Asia-Pacific Oncology Precision Medicine Market
4.4.4 China
4.4.5 India
4.4.6 Japan
4.4.7 Australia
4.4.8 South Korea
4.4.9 Rest-of-Asia-Pacific
4.5 Latin America (LATAM)
4.5.1 Key Competitors (by Ecosystem)
4.5.2 Latin America Oncology Precision Medicine Market (by Application)
4.5.3 Key Trends in the Latin America Oncology Precision Medicine Market
4.5.4 Brazil
4.5.5 Mexico
4.5.6 Rest-of-Latin America
4.6 Rest-of-the-World (RoW)
4.6.1 Key Competitors (by Ecosystem)
4.6.2 Rest-of-the-World Oncology Precision Medicine Market (by Application)
4.6.3 Key Trends in the Rest-of-the-World Oncology Precision Medicine Market
5 Markets - Competitive Benchmarking & Company Profiles
5.1 Overview
5.2 Agilent Technologies, Inc.
5.2.1 Company Overview
5.2.2 Role of Agilent Technologies, Inc. in the Global Oncology Precision Medicine Market
5.2.3 Key Competitors of the Company
5.2.4 Financials
5.2.5 Key Insights About Financial of the Company
5.2.6 Corporate Strategies
5.2.6.1 Mergers and Acquisitions
5.2.6.2 Synergistic Activities
5.2.6.3 Business Expansion and Funding
5.2.6.4 Product Launches and Upgradation
5.2.7 SWOT Analysis
5.3 Bio-Rad Laboratories, Inc.
5.3.1 Company Overview
5.3.2 Role of Bio-Rad Laboratories, Inc. in the Global Oncology Precision Medicine Market
5.3.3 Key Competitors of the Company
5.3.4 Financials
5.3.5 Key Insights About Financial Health of the Company
5.3.6 Corporate Strategies
5.3.6.1 Product Launches and upgradation
5.3.7 SWOT Analysis
5.4 Illumina, Inc.
5.4.1 Company Overview
5.4.2 Role of Illumina, Inc. in the Global Oncology Precision Medicine Market
5.4.3 Key Competitors of the Company
5.4.4 Financials
5.4.5 Key Insights About Financial Health of the Company
5.4.6 Corporate Strategies
5.4.6.1 Mergers and Acquisition
5.4.6.2 Synergistic Activities
5.4.6.3 Business Expansion and Funding
5.4.6.4 Product Launches and Upgradation
5.4.7 SWOT Analysis
5.5 Pacific Biosciences of California, Inc.
5.5.1 Company Overview
5.5.2 Role of Pacific Biosciences of California, Inc. in the Global Oncology Precision Medicine Market
5.5.3 Key Competitors of the Company
5.5.4 Financials
5.5.5 Key Insights About Financial Health of the Company
5.5.6 Corporate Strategies
5.5.6.1 Mergers and Acquisition
5.5.6.2 Synergistic Activities
5.5.6.3 Product Launches and Upgradation
5.5.7 SWOT Analysis
5.6 PerkinElmer Inc.
5.6.1 Company Overview
5.6.2 Role of PerkinElmer Inc. in the Global Oncology Precision Medicine Market
5.6.3 Key Competitors of the Company
5.6.4 Financials
5.6.5 Key Insights About Financial Health of the Company
5.6.6 Corporate Strategies
5.6.6.1 Mergers and Acquisition:
5.6.6.2 Synergistic Activities
5.6.6.3 Business Expansion and Funding
5.6.6.4 Product Launches and Upgradation
5.6.7 SWOT Analysis
5.7 QIAGEN
5.7.1 Company Overview
5.7.2 Role of QIAGEN in the Global Oncology Precision Medicine Market
5.7.3 Key Competitors of the Company
5.7.4 Financials
5.7.5 Key Insights About Financial Health of the Company
5.7.6 Corporate Strategies
5.7.6.1 Mergers and Acquisition
5.7.6.2 Synergistic Activities
5.7.6.3 Business Expansion and Funding
5.7.6.4 Product Launches and Upgradation
5.7.7 SWOT Analysis
5.8 Thermo Fisher Scientific Inc.
5.8.1 Company Overview
5.8.2 Role of Thermo Fisher Scientific Inc. in the Global Oncology Precision Medicine Market
5.8.3 Key Competitors of the Company
5.8.4 Financials
5.8.5 Key Insights About Financial Health of the Company
5.8.6 Corporate Strategies
5.8.6.1 Mergers and Acquisition
5.8.6.2 Synergistic Activities
5.8.6.3 Business Expansion and Funding
5.8.6.4 Product Launches and Upgradation
5.8.7 SWOT Analysis
5.9 BGI Group
5.9.1 Company Overview
5.9.2 Role of BGI Group in the Global Oncology Precision Medicine Market
5.9.3 Key Competitors of the Company
5.9.4 Corporate Strategies
5.9.4.1 Mergers and Acquisitions
5.9.4.2 Synergistic Activities
5.9.4.3 Business Expansion and Funding
5.9.4.4 Product Launches and Upgradation
5.9.5 SWOT Analysis
5.1 ASURAGEN, INC.
5.10.1 Company Overview
5.10.2 Role of ASURAGEN, INC. in Global Oncology Precision Medicine Market
5.10.3 Key Competitors of the Company
5.10.4 Corporate Strategies
5.10.4.1 Synergistic Activities
5.10.4.2 Business Expansion and Funding
5.10.4.3 Product Launches and Upgradation
5.10.5 SWOT Analysis
5.11 Almac Group Ltd.
5.11.1 Company Overview
5.11.2 Role of Almac Group Ltd. in Global Oncology Precision Medicine Market
5.11.3 Key Competitors of the Company
5.11.4 Corporate Strategies
5.11.4.1 Mergers and Acquisitions
5.11.4.2 Synergistic Activities
5.11.4.3 Business Expansion and Funding
5.11.4.4 Product Launches and Upgradation
5.11.5 SWOT Analysis
5.12 MDxHealth
5.12.1 Company Overview
5.12.2 Role of MDxHealth in the Global Oncology Precision Medicine Market
5.12.3 Key Competitors of the Company
5.12.4 Financials
5.12.5 Key Insights About Financial Health of the Company
5.12.6 Corporate Strategies
5.12.6.1 Mergers and Acquisitions
5.12.6.2 Synergistic Activities
5.12.6.3 Business Expansion and Funding
5.12.6.4 Product Launches and Upgradation
5.12.7 SWOT Analysis
5.13 Abbott Laboratories
5.13.1 Company Overview
5.13.2 Role of Abbott Laboratories in the Global Oncology Precision Medicine Market
5.13.3 Key Competitors of the Company
5.13.4 Financials
5.13.5 Corporate Strategies
5.13.5.1 Mergers and Acquisitions
5.13.5.2 Synergistic Activities
5.13.5.3 Business Expansion and Funding
5.13.5.4 Product launches and Upgradation
5.13.6 SWOT Analysis
5.14 F. Hoffmann-La Roche Ltd
5.14.1 Company Overview
5.14.2 Role of F. Hoffman-LA Roche Ltd in the Global Oncology Precision Medicine Market
5.14.3 Key Competitors of the Company
5.14.4 Financials
5.14.5 Corporate Strategies
5.14.5.1 Mergers and Acquisitions
5.14.5.2 Synergistic Activities
5.14.5.3 Business Expansion and Funding
5.14.5.4 Product Launches and Upgradation
5.14.6 SWOT Analysis
5.15 Gilead Sciences, Inc.
5.15.1 Company Overview
5.15.2 Role of Gilead Sciences, Inc. in the Global Oncology Precision Medicine Market
5.15.3 Key Competitors of the Company
5.15.4 Financials
5.15.5 Corporate Strategies
5.15.5.1 Mergers and Acquisitions
5.15.5.2 Synergistic Activities
5.15.5.3 Business Expansion and Funding
5.15.5.4 Product Launches and Upgradation
5.15.6 SWOT Analysis
5.16 Myriad Genetics, Inc
5.16.1 Company Overview
5.16.2 Role of Myriad Genetics, Inc. in the Global Oncology Precision Medicine Market
5.16.3 Key Competitors of the Company
5.16.4 Financials
5.16.5 Key Insights About Financial Health of the Company
5.16.6 Corporate Strategies
5.16.6.1 Mergers and Acquisitions
5.16.6.2 Synergistic Activities
5.16.6.3 Business Expansion and Funding
5.16.6.4 Product Launches and Upgradation
5.16.7 SWOT Analysis
5.17 OPKO Health, Inc.
5.17.1 Company Overview
5.17.2 Role of OPKO Health, Inc. in the Global Oncology Precision Medicine Market
5.17.3 Key Competitors of the Company
5.17.4 Financials
5.17.5 Corporate Strategies
5.17.5.1 Mergers and Acquisitions
5.17.5.2 Synergistic Activities
5.17.5.3 Business Expansion and Funding
5.17.5.4 Product Launches and Upgradation
5.17.6 SWOT Analysis
5.18 Quest Diagnostics Incorporated
5.18.1 Company Overview
5.18.2 Role of Quest Diagnostics Incorporated in the Global Oncology Precision Medicine Market
5.18.3 Key Competitors of the Company
5.18.4 Financials
5.18.5 Corporate Strategies
5.18.5.1 Mergers and Acquisitions
5.18.5.2 Synergistics Activities
5.18.5.3 Business Expansion and Funding
5.18.5.4 Product Launches and Upgradation
5.18.6 SWOT Analysis
5.19 Novartis AG
5.19.1 Company Overview
5.19.2 Role of Novartis AG in the Global Oncology Precision Medicine Market
5.19.3 Key Competitors of the Company
5.19.4 Financials
5.19.5 Corporate Strategies
5.19.5.1 Synergistic Activities
5.19.5.2 Business Expansion and Funding
5.19.5.3 Product Launches and Upgradation
5.19.6 SWOT Analysis
5.2 Emerging Companies
5.20.1 Prelude Therapeutics
5.20.1.1 Company Overview
5.20.2 AceTech
5.20.2.1 Company Overview
5.20.3 Flatiron
5.20.3.1 Company Overview
5.20.4 Biosplice Therapeutics, Inc.
5.20.4.1 Company Overview
List of Figures
Figure 1: Overall Deaths Due to Key Cancer Causes, Million, 2012-2019
Figure 2: Global Oncology Precision Medicine Market, $Million, 2020-2031
Figure 3: Global Oncology Precision Medicine Market, Market Dynamics
Figure 4: Share of Key Developments and Strategies, January 2018-January 2022
Figure 5: Global Oncology Precision Medicine Market (by Ecosystem), $Million, 2020 Vs. 2031
Figure 6: Global Oncology Precision Medicine Market (by Application), $Million, 2020 Vs. 2031
Figure 7: Global Oncology Precision Medicine Market (by Region), 2020 Vs. 2031
Figure 8: Global Oncology Precision Medicine Market Research Methodology
Figure 9: Share of Total Number of Companies Profiled
Figure 10: Global Oncology Precision Medicine Market: Segmentation
Figure 11: Global Oncology Precision Medicine Market, $Million, 2020-2031
Figure 12: Evolution of Precision Medicine Technology
Figure 13: Molecular Diagnostics in Oncology
Figure 14: Number of Cancer Cases Diagnosed in the Netherlands (January 3, 2020 - April 5 2020)
Figure 15: Pre-COVID-19 and Post-COVID-19 Scenario of Global Oncology Precision Medicine Market, 2017-2025
Figure 16: Areas of Disruption in Clinical Development
Figure 17: Measure to Navigate Crisis Recovery
Figure 18: Global Oncology Precision Medicine Market - Market Dynamics
Figure 19: Estimated Tracheal, Bronchus and Lung Cancer Incidences (Region-Wise), 2020 and 2030(E)
Figure 20: Estimated Cancer Mortality (Region-Wise), 2020
Figure 21: Decreasing Cost and Increasing Output of Genome Sequencing, 2009-2025
Figure 22: Share of Key Developments and Strategies, January 2018-January 2022
Figure 23: Share of Acquisitions (by Company), January 2018-January 2022
Figure 24: Synergistic Activities Share (by Company), January 2018-January 2022
Figure 25: Product Launches and Approvals (by Company), January 2018–January 2022
Figure 26: Share of Business Expansion (by Company), January 2018-January 2022
Figure 27: Market Share Analysis for Global Oncology Precision Medicine Market, $Million, 2020
Figure 28: Growth Share Analysis of Global Oncology Precision Medicine Market (by Application), 2021-2031
Figure 29: Growth Share Analysis of Global Oncology Precision Medicine Market (by Ecosystem), 2021-2031
Figure 30: FDA Guidelines for CDx Approval
Figure 31: Year-Wise Analysis of Patents Related to Oncology Precision Medicine, January 2018-January 2022
Figure 32: Region-Wise Analysis of Patents Related to Oncology Precision Medicine, January 2018 - January 2022
Figure 33: Country-Wise Analysis of Patents Related to Oncology Precision Medicine, January 2018 - January 2022
Figure 34: Share of Global Oncology Precision Medicine Market (by Ecosystem), $Million, 2020 and 2031
Figure 35: Global Oncology Precision Medicine Market (Precision Therapeutics), $Million, 2020-2031
Figure 36: Global Oncology Precision Medicine Market (Clinical Trials), $Million, 2020-2031
Figure 37: Global Oncology Precision Medicine Market (Biomarker Testing), $Million, 2020-2031
Figure 38: Global Oncology Precision Medicine Market (Drug Discovery and Research), $Million, 2020-2031
Figure 39: Global Oncology Precision Medicine Market (Gene Therapy), $Million, 2020-2031
Figure 40: Global Oncology Precision Medicine Market (Cell Therapy), $Million, 2020-2031
Figure 41: Global Oncology Precision Medicine Market (Applied Sciences), $Million, 2020-2031
Figure 42: Global Oncology Precision Medicine Market (Genomics), $Million, 2020-2031
Figure 43: Global Oncology Precision Medicine Market (PCR), $Million, 2020-2031
Figure 44: Global Oncology Precision Medicine Market (Precision Medicine NGS), $Million, 2020-2031
Figure 45: Global Oncology Precision Medicine Market (Genome Editing), $Million, 2020-2031
Figure 46: Global Oncology Precision Medicine Market (Other Technologies) $Million, 2020-2031
Figure 47: Global Oncology Precision Medicine Market (Pharmacogenomics), $Million, 2020-2031
Figure 48: Global Oncology Precision Medicine Market (Other Applied Sciences), $Million, 2020-2031
Figure 49: Global Oncology Precision Medicine Market (Digital Health and Information Technology), $Million, 2020-2031
Figure 50: Global Oncology Precision Medicine Market (CDSS), $Million, 2020-2031
Figure 51: Global Oncology Precision Medicine Market (Big Data Analytics), $Million, 2020-2031
Figure 52: Global Oncology Precision Medicine Market (IT Infrastructure), $Million, 2020-2031
Figure 53: Global Oncology Precision Medicine Market (Genomics Informatics), $Million, 2020-2031
Figure 54: Global Oncology Precision Medicine Market (In-Silico Informatics), $Million, 2020-2031
Figure 55: Global Oncology Precision Medicine Market (Mobile Health), $Million, 2020-2031
Figure 56: Global Oncology Precision Medicine Market (Precision Diagnostics), $Million, 2020-2031
Figure 57: Global Oncology Precision Medicine Market (Molecular Diagnostics), $Million, 2020-2031
Figure 58: Global Oncology Precision Medicine Market (Medical Imaging), $Million, 2020-2031
Figure 59: Global Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
Figure 60: Global Oncology Precision Medicine Market (Solid Tumor), $Million, 2020-2031
Figure 61: Global Oncology Precision Medicine Market (Breast Cancer), $Million, 2020-2031
Figure 62: Global Oncology Precision Medicine Market (Lung Cancer), $Million, 2020-2031
Figure 63: Global Oncology Precision Medicine Market (Colorectal Cancer), $Million, 2020-2031
Figure 64: Global Oncology Precision Medicine Market (Prostate Cancer), $Million, 2020-2031
Figure 65: Global Oncology Precision Medicine Market (Cervical Cancer), $Million, 2020-2031
Figure 66: Global Oncology Precision Medicine Market (Other Cancer), $Million, 2020-2031
Figure 67: Global Oncology Precision Medicine Market (Hematological Malignancies), $Million, 2020-2031
Figure 68: Global Oncology Precision Medicine Market (Leukemia), $Million, 2020-2031
Figure 69: Global Oncology Precision Medicine Market (Lymphoma), $Million, 2020-2031
Figure 70: Global Oncology Precision Medicine Market (Myeloma), $Million, 2020-2031
Figure 71: Global Oncology Precision Medicine Market (Other Hematological Malignancies), $Million, 2020-2031
Figure 72: Global Oncology Precision Medicine Market (by Region), 2020-2031
Figure 73: Share of North America Oncology Precision Medicine Market (by Country), $Million, 2020 and 2031
Figure 74: North America: Market Dynamics
Figure 75: North America Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
Figure 76: U.S. Oncology Precision Medicine Market, $Million, 2020-2031
Figure 77: Canada Oncology Precision Medicine Market, $Million, 2020-2031
Figure 78: Europe Oncology Precision Medicine Market (by Country), $Million, 2020 and 2031
Figure 79: Europe: Market Dynamics
Figure 80: Europe Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
Figure 81: Germany Oncology Precision Medicine Market, $Million, 2020-2031
Figure 82: U.K. Oncology Precision Medicine Market, Million, 2020-2031
Figure 83: France Oncology Precision Medicine Market, $Million, 2020-2031
Figure 84: Italy Oncology Precision Medicine Market, $Million, 2020-2031
Figure 85: Spain Oncology Precision Medicine Market, $Million, 2020-2031
Figure 86: Rest-of-Europe Oncology Precision Medicine Market, $Million, 2020-2031
Figure 87: APAC: Market Dynamics
Figure 88: Asia-Pacific Oncology Precision Medicine Market (by Country), $Million, 2020 and 2031
Figure 89: Asia-Pacific Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
Figure 90: China Oncology Precision Medicine Market, $Million, 2020-2031
Figure 91: India Oncology Precision Medicine Market, $Million, 2020-2031
Figure 92: Japan Oncology Precision Medicine Market, $Million, 2020-2031
Figure 93: Australia Oncology Precision Medicine Market, Million, 2020-2031
Figure 94: South Korea Oncology Precision Medicine Market, Million, 2020-2031
Figure 95: Rest-of-Asia-Pacific Oncology Precision Medicine Market, $Million, 2020-2031
Figure 96: LATAM: Market Dynamics
Figure 97: Latin America Oncology Precision Medicine Market (by Country), $Million, 2020-2031
Figure 98: Latin America Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
Figure 99: Brazil Oncology Precision Medicine Market, $Million, 2020-2031
Figure 100: Mexico Oncology Precision Medicine Market, Million, 2020-2031
Figure 101: Rest-of-Latin America Oncology Precision Medicine Market, $Million, 2020-2031
Figure 102: Rest-of-the-World Oncology Precision Medicine Market, $Million, 2020-2031
Figure 103: Rest-of-the-World Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
Figure 104: Share of Key Company Profiled (22)
Figure 105: Agilent Technologies, Inc.: Product Portfolio
Figure 106: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
Figure 107: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 108: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 109: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 110: Agilent Technologies, Inc.: SWOT Analysis
Figure 111: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 112: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2018-2020
Figure 113: Bio-Rad Laboratories, Inc.: Revenue (by Business Segment), $Million, 2018-2020
Figure 114: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 115: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 116: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 117: Illumina, Inc.: Product Portfolio
Figure 118: Illumina, Inc.: Overall Financials, $Million, 2018-2020
Figure 119: Illumina, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 120: Illumina, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 121: Illumina, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 122: Illumina, Inc.: SWOT Analysis
Figure 123: Pacific Biosciences of California, Inc.: Product Portfolio
Figure 124: Pacific Biosciences of California, Inc.: Overall Financials, $Million, 2018-2020
Figure 125: Pacific Biosciences of California, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 126: Pacific Biosciences of California, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 127: Pacific Biosciences of California, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 128: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 129: PerkinElmer Inc.: Product Portfolio
Figure 130: PerkinElmer Inc.: Overall Financials, $Million, 2018-2020
Figure 131: PerkinElmer Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 132: PerkinElmer Inc: Revenue (by Region), $Million, 2018-2020
Figure 133: PerkinElmer Inc. R&D Expenditure, $Million, 2018-2020
Figure 134: PerkinElmer Inc.: SWOT Analysis
Figure 135: QIAGEN: Portfolio
Figure 136: QIAGEN: Overall Financials, $Million, 2018-2020
Figure 137: QIAGEN: Revenue (by Segment), $Million, 2018-2020
Figure 138: QIAGEN: Revenue (by Region), $Million, 2018-2020
Figure 139: QIAGEN: R&D Expenditure, $Million, 2018-2020
Figure 140: QIAGEN: SWOT Analysis
Figure 141: Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 142: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2018-2020
Figure 143: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2018-2020
Figure 144: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018-2020
Figure 145: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020
Figure 146: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 147: BGI Product Portfolio
Figure 148: BGI Group: SWOT Analysis
Figure 149: ASURAGEN, INC.: Overall Product Offerings
Figure 150: ASURAGEN,INC.: SWOT Analysis
Figure 151: Almac Group Ltd.: Overall Product Offerings
Figure 152: Almac Group Ltd.: SWOT Analysis
Figure 153: MDxHealth: Service Portfolio
Figure 154: MDxHealth: Overall Financials, $Million, 2018-2020
Figure 155: MDxHealth: Revenue (by Segment), $Million, 2018-2020
Figure 156: MDxHealth: Revenue (by Region), $Million, 2018-2020
Figure 157: MDxHealth: R&D Expenditure, $Million, 2018-2020
Figure 158: MdxHealth: SWOT Analysis
Figure 159: Abbott Laboratories: Overall Product Offerings
Figure 160: Abbott Laboratories: Overall Financials, $Million, 2018-2020
Figure 161: Abbott Laboratories: Net Revenue (by Business Segment), $Million, 2018-2020
Figure 162: Abbott Laboratories: Net Revenue (by Region), $Million, 2018-2020
Figure 163: Abbott Laboratories: R&D Expenditure, $Million, 2018-2020
Figure 164: Abbott Laboratories: SWOT Analysis
Figure 165: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 166: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 167: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
Figure 168: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
Figure 169: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 170: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 171: Gilead Sciences, Inc.: Overall Product Portfolio
Figure 172: Gilead Sciences, Inc.: Overall Financials, $Million, 2018-2020
Figure 173: Gilead Sciences, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 174: Gilead Sciences, Inc.: SWOT Analysis
Figure 175: Myriad Genetics, Inc.: Product Portfolio
Figure 176: Myriad Genetics, Inc.: Overall Financials, $Million, 2018-2020
Figure 177: Myriad Genetics, Inc.: Revenue (by Business Segment), $Million, 2018-2020
Figure 178: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 179: Myriad Genetics, Inc.: SWOT Analysis
Figure 180: OPKO Health, Inc.: Overall Product Portfolio
Figure 181: OPKO Health, Inc.: Overall Financials, $Million, 2018-2020
Figure 182: OPKO Health, Inc: Net Revenue (by Business Segment), $Million, 2018-2020
Figure 183: OPKO Health, Inc.: Net Revenue (by Region), $Million, 2018-2020
Figure 184: OPKO Health, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 185: OPKO Health, Inc.: SWOT Analysis
Figure 186: Quest Diagnostics Incorporated: Overall Product Offerings
Figure 187: Quest Diagnostics Incorporated: Overall Financials, $Million, 2018-2020
Figure 188: Quest Diagnostics Incorporated: Revenue (by Business Segment), $Million, 2018-2020
Figure 189: Quest Diagnostics Incorporated: SWOT Analysis
Figure 190: Novartis AG: Overall Product Portfolio
Figure 191: Novartis AG: Overall Financials, $Million, 2019-2021
Figure 192: Novartis AG: Revenue (by Business Segment), $Million, 2019-2021
Figure 193: Novartis AG: SWOT Analysis
List of Tables
Table 1: Estimated New Cancer Cases (by Type) in U.S., 2022
Table 2: Potential Usage of Biomarkers in Cancer Diagnostics
Table 3: List of Initiatives for Precision Oncology Research in 2018
Table 4: List of Few FDA-Approved Pharmacogenomics Biomarkers in Drug Labeling
Table 5: Estimated New Cancer Cases and Deaths in the U.S., 2020
Table 6: Key Competitors of North America Oncology Precision Medicine (by Ecosystem), 2020
Table 7: Key Competitors of Europe Oncology Precision Medicine (by Ecosystem), 2020
Table 8: Key Competitors of Asia-Pacific Oncology Precision Medicine (by Ecosystem), 2020
Table 9: Key Competitors of Latin America Oncology Precision Medicine (by Ecosystem), 2020
Table 10: Key Competitors of Rest-of-the-World Oncology Precision Medicine (by Ecosystem), 2020
Table 11: BIS Insight for Prelude Therapeutics
Table 12: BIS Insight for AceTech
Table 13: BIS Insight for Flatiron
Table 14: BIS Insight for Biosplice Therapeutics, Inc.
Companies Mentioned
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Illumina, Inc.
- Pacific Biosciences of California, Inc.
- PerkinElmer Inc.
- QIAGEN
- Thermo Fisher Scientific Inc.
- BGI Group
- ASURAGEN, INC.
- Almac Group Ltd.
- MDxHealth
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- Myriad Genetics, Inc.
- OPKO Health, Inc.
- Quest Diagnostics Incorporated
- Novartis AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 273 |
| Published | March 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 49464.5 Million |
| Forecasted Market Value ( USD | $ 128961.6 Million |
| Compound Annual Growth Rate | 10.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
